MTOR and nonpapillary renal cell carcinoma: While targeted therapies such as tyrosine kinase inhibitors (sunitinib, sorafinib, pazopanib, axitinib, tivozanib) and mammalian target of rapamycin (mTOR) inhibitors (everolimus, sirolimus, temsirolimus) have greatly improved the prognosis of metastatic Clear Cell Renal Carcinoma (ccRCC) patients, the average duration of disease control ranges between 8–9 months in the first-line setting and 5–6 months in the second-line setting1.